For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Biogen, Incorporated

USPTO Granted Patents = 130

% Expired Patents = 9.2

CIPO Patents = 3

EPO Patents = 1

Trademarks = 3

Forward Citations = 3,205

Loading Chart...

Loading Chart...

168 inventors (with patents filed for the assignee):

Barbara P Wallner (15 out of 34 patents)

Catherine A Hession (12 out of 19 patents)

John M Maraganore (11 out of 11 patents)

4. R Blake Pepinsky (10 out of 51 patents)

5. Wen-Cherng Lee (10 out of 25 patents)

6. Jeffrey L Browning (10 out of 43 patents)

7. Steven P Adams (10 out of 50 patents)

8. Alfredo C Castro (9 out of 114 patents)

9. Ko-Chung Lin (9 out of 18 patents)

10. Richard L Cate (9 out of 11 patents)

11. James G Barsoum (9 out of 27 patents)

12. Margaret D Rosa (9 out of 13 patents)

13. Roy R Lobb (9 out of 29 patents)

14. Craig N Zimmerman (8 out of 37 patents)

15. Christopher D Benjamin (8 out of 15 patents)

Core Competencies:

Immunotherapy

Anti-CD20 Antibodies

Cell Adhesion Inhibitors

Inflammatory Diseases

VLA-4 Blockers

Gene Therapy

Lymphotoxin

Adenosine Receptor Antagonists

Fibrosis Treatment

Hepatitis B Virus Inhibitors

Cancer Treatment

Biologic Therapies

130 patents: Sort by Forward Citations

1. 11192856 - Process for preparing alpha-carboxamide pyrrolidine derivatives (2021-12-07),

2. 11149039 - Process for preparing spiro derivatives (2021-10-19),

3. 10654940 - Method for treating joint damage (2020-05-19),

4. 10450379 - Method for treating joint damage (2019-10-22),

5. 10400043 - Treatment of diffuse large-cell lymphoma with anti-CD20 antibody (2019-09-03),

6. 10113000 - Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody (2018-10-30),

7. 9504744 - Treatment of diffuse large-cell lymphoma with anti-CD20 antibody (2016-11-29),

8. 9493567 - Methods of treating inflammatory and autoimmune diseases with natalizumab (2016-11-15),

9. 9296821 - Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibodies (2016-03-29),

10. 9198955 - Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen (2015-12-01),

11. 7255854 - Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases (2007-08-14),

12. 7173046 - CD40:CD154 binding interrupter compounds and use thereof to treat immunological complications (2007-02-06),

13. 7112665 - Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants (2006-09-26),

14. 7030080 - Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof (2006-04-18),

15. 6962978 - Polymer conjugates of interferon beta-1a and uses (2005-11-08),

Biogen is a global biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases. With a commitment to scientific excellence and a focus on pioneering treatments, Biogen is dedicated to improving the lives of patients and caregivers.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Biogen, Incorporated

130 Patents

#20 in Cambridge, MA

#159 in Massachusetts

#2,974 in US

#6,168 in the World

Cambridge, MA, United States of America

Biogen, Incorporated

Forward Citations = 3,205

168 inventors:

Barbara P Wallner (15 out of 34 patents)

Catherine A Hession (12 out of 19 patents)

John M Maraganore (11 out of 11 patents)

4. R Blake Pepinsky (10 out of 51 patents)

5. Wen-Cherng Lee (10 out of 25 patents)

Please report any incorrect information to [email protected]

Loading…